Medical Cannabis Access Cuts Health-Related Work Absences 7%, UGA Study Finds

Study Design and Data Scope

The University of Georgia research team analyzed longitudinal data spanning 35 years and 20 million survey responses to isolate the impact of medical cannabis laws on workforce absenteeism. Researchers drew from the Current Population Survey, a joint Census Bureau and Bureau of Labor Statistics dataset tracking employment, health status, and work absences. They compared absence rates in states before and after medical cannabis laws took effect, controlling for demographic shifts, economic cycles, and state-level health trends.

The 7% reduction represents approximately 2.1 fewer absence days per 100 workers annually in medical cannabis states. That's roughly 14 million fewer missed workdays nationwide per year, based on current labor force participation.

Strongest Effect in Physical-Labor Sectors

The absenteeism decline was most pronounced among workers in physically demanding occupations, where chronic pain and musculoskeletal conditions drive the majority of health-related absences. Construction, manufacturing, and warehousing sectors showed reductions between 9% and 11%. Office-based roles saw 4-5%.

Treatment substitution offers the cleanest explanation. Workers managing pain with opioids or over-the-counter anti-inflammatories face higher rates of side effects, tolerance, and rebound symptoms that trigger absences. Medical cannabis appears to offer a functional alternative for conditions like lower back pain, arthritis, and repetitive strain injuries.

Researchers didn't track individual patient records or cannabis use directly, relying instead on state-level policy changes as the independent variable. That design limits causal claims but strengthens the signal by eliminating self-selection bias.

Economic Implications for Employers

The 7% reduction in health-related absences carries direct cost implications for employers, who absorb an estimated $225 billion annually in lost productivity from worker absenteeism. A 7% reduction would save U.S. businesses approximately $15.75 billion per year if the effect held across all states.

Employers in medical cannabis states also face lower workers' compensation claims and disability insurance premiums when employees substitute cannabis for opioids, according to prior research cited in the UGA study. The numbers are straightforward: fewer absences, lower comp costs, and reduced opioid-related workplace incidents.

Federal prohibition remains the friction point. Employers in safety-sensitive industries—transportation, aviation, heavy machinery—can't accommodate medical cannabis use under Department of Transportation and Occupational Safety and Health Administration rules, even in states with legal programs. That gap limits the workplace productivity gains to non-federally regulated sectors.

Policy Context and State Variance

The study's 35-year timeframe captures the full arc of state medical cannabis adoption, from California's 1996 Compassionate Use Act to the 38 states with active programs today. Researchers found no statistically significant difference in absenteeism effects between early-adopter states and recent entrants, suggesting the benefit is tied to access itself rather than program maturity.

State variance in qualifying conditions, possession limits, and dispensary density didn't meaningfully alter the 7% baseline effect. That uniformity supports the hypothesis that medical cannabis is addressing unmet pain management needs across diverse patient populations.

For full background on this story, see the CannIntel topic hub on Medical Cannabis and Workplace Productivity.

What This Means for the Federal Rescheduling Debate

The UGA findings arrive as the DEA considers rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act, a move that would expand medical research access and potentially shift employer accommodation rules. Rescheduling wouldn't eliminate federal workplace drug testing prohibitions, but it could open the door for states to mandate reasonable accommodations for off-duty medical cannabis use, similar to protections for prescription medications.

Watch for this signal: whether the DEA's final rule on rescheduling includes guidance for employers on medical cannabis accommodation in non-safety-sensitive roles. That guidance has been absent from every draft NPRM to date.

The political variable nobody can model is whether a 7% productivity gain is sufficient to shift employer lobbying groups—historically aligned with prohibition—toward neutrality or support for medical cannabis access. The Chamber of Commerce hasn't taken a position.